Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor
Copyright © 2020 Elsevier B.V. All rights reserved..
Since only a minority of patients may respond to single-agent therapies, methods to test the potential antitumor activity of rational combination therapies are still needed. This study aimed to characterize the efficacy of antitumor combination therapies in vivo within the primary tumor using patient-derived xenograft (PDX) models by gamma-irradiation-induced immune suppression. We employed four Luminal A PDX models obtained from human mammary tumors grown in mice. PDX models were implanted into the right flank of mice, and treatments have ensued once tumor volume reached ~150 mm3. Four of the active drugs- Adriamycin, Cyclophosphamide, Taxotere, and Tamoxifen-were tested in vivo to treat mammary tumors. The tumor volume was measured during the study. The mice's immune system was inherently suppressed by gamma irradiation, thus allowing human tumors to grow. The results showed that the tumorigenesis rate of the PDX model was from 65 to 80%. PDX models were successfully established with a high frequency of tumor engraftment. Humanized mice treated with a two-drug regimen, that is, adriamycin + cyclophosphamide exhibited an increased antitumor response than a three-drug regimen, that is, adriamycin + cyclophosphamide + taxotere that correlated with tumor growth inhibition. Combination therapies with adriamycin + cyclophosphamide in PDX mice reduced tumor growth in four Luminal A PDX models. These preclinical results suggest that a two-drug regimen than a three-drug regimen can be useful for breast cancer patients. This study provides insights for future studies combining chemotherapeutics with targeted therapies using PDX models by gamma-irradiation-induced immune suppression.
Errataetall: |
RetractionIn: Eur J Pharmacol. 2024 Apr 15;969:176350. - PMID 38458940 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:889 |
---|---|
Enthalten in: |
European journal of pharmacology - 889(2020) vom: 15. Dez., Seite 173605 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Khalighfard, Solmaz [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antineoplastic Agents |
---|
Anmerkungen: |
Date Completed 14.05.2021 Date Revised 21.03.2024 published: Print-Electronic RetractionIn: Eur J Pharmacol. 2024 Apr 15;969:176350. - PMID 38458940 Citation Status MEDLINE |
---|
doi: |
10.1016/j.ejphar.2020.173605 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM31551065X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM31551065X | ||
003 | DE-627 | ||
005 | 20240321234906.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ejphar.2020.173605 |2 doi | |
028 | 5 | 2 | |a pubmed24n1338.xml |
035 | |a (DE-627)NLM31551065X | ||
035 | |a (NLM)32980347 | ||
035 | |a (PII)S0014-2999(20)30697-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Khalighfard, Solmaz |e verfasserin |4 aut | |
245 | 1 | 0 | |a Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.05.2021 | ||
500 | |a Date Revised 21.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a RetractionIn: Eur J Pharmacol. 2024 Apr 15;969:176350. - PMID 38458940 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
520 | |a Since only a minority of patients may respond to single-agent therapies, methods to test the potential antitumor activity of rational combination therapies are still needed. This study aimed to characterize the efficacy of antitumor combination therapies in vivo within the primary tumor using patient-derived xenograft (PDX) models by gamma-irradiation-induced immune suppression. We employed four Luminal A PDX models obtained from human mammary tumors grown in mice. PDX models were implanted into the right flank of mice, and treatments have ensued once tumor volume reached ~150 mm3. Four of the active drugs- Adriamycin, Cyclophosphamide, Taxotere, and Tamoxifen-were tested in vivo to treat mammary tumors. The tumor volume was measured during the study. The mice's immune system was inherently suppressed by gamma irradiation, thus allowing human tumors to grow. The results showed that the tumorigenesis rate of the PDX model was from 65 to 80%. PDX models were successfully established with a high frequency of tumor engraftment. Humanized mice treated with a two-drug regimen, that is, adriamycin + cyclophosphamide exhibited an increased antitumor response than a three-drug regimen, that is, adriamycin + cyclophosphamide + taxotere that correlated with tumor growth inhibition. Combination therapies with adriamycin + cyclophosphamide in PDX mice reduced tumor growth in four Luminal A PDX models. These preclinical results suggest that a two-drug regimen than a three-drug regimen can be useful for breast cancer patients. This study provides insights for future studies combining chemotherapeutics with targeted therapies using PDX models by gamma-irradiation-induced immune suppression | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Retracted Publication | |
650 | 4 | |a Breast cancer | |
650 | 4 | |a Chemotherapy | |
650 | 4 | |a Mice | |
650 | 4 | |a Patient-derived xenograft | |
650 | 4 | |a Pre-clinical | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
700 | 1 | |a Alizadeh, Ali Mohammad |e verfasserin |4 aut | |
700 | 1 | |a Poorkhani, Amirhoushang |e verfasserin |4 aut | |
700 | 1 | |a Motahari, Mohammadmehdi |e verfasserin |4 aut | |
700 | 1 | |a Tahmasebifar, Arash |e verfasserin |4 aut | |
700 | 1 | |a Omranipour, Ramesh |e verfasserin |4 aut | |
700 | 1 | |a Keshavarz, Pedram |e verfasserin |4 aut | |
700 | 1 | |a Haddad, Peiman |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 889(2020) vom: 15. Dez., Seite 173605 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
773 | 1 | 8 | |g volume:889 |g year:2020 |g day:15 |g month:12 |g pages:173605 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2020.173605 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 889 |j 2020 |b 15 |c 12 |h 173605 |